Immunotherapy: Clinical Trials

3 trials for Immunotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Unknown 3
Phase 21Unknown 1

Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy
Phase 2 / Phase 3UnknownTaizhou Hospital602022-07-012023-04-18
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML
Visilizumab - Immunotherapy, Refractory Leukemia
Phase 3UnknownThe First Affiliated Hospital of Soochow University302021-05-012021-12-03
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
Sintilimab, Bevacizumab - HCC, Adjuvant Therapy
Phase 3UnknownSun Yat-sen University2462020-12-012020-12-23

Narrower conditions

Esophageal Neoplasms (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Recurrence (1)

Broader conditions

Neoplasms (2)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Disease Attributes (1)  ·  Esophageal Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Leukemia, Myeloid (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Azacitidine (1)  ·  Bevacizumab (1)  ·  Cytarabine (1)  ·  Homoharringtonine (1)  ·  Radiation (1)  ·  S 1 (combination) (1)  ·  Tegafur (1)  ·  sintilimab (1)  ·  toripalimab (1)  ·  visilizumab (1)

Sponsors

Sun Yat-sen University (1)  ·  Taizhou Hospital (1)  ·  The First Affiliated Hospital of Soochow University (1)

Countries

China (3)

Top investigators

Han Yue, Ph.D (1)